

### Marine Pharmacology in 1998: Antitumor and Cytotoxic Compounds

Alejandro M.S. Mayer, Ph.D.<sup>1</sup>

#### Introduction

During 1998 marine antitumor pharmacology research involved research groups in Austria, Australia, Chile, England, France, Germany, Holland, Israel, Italy, Japan, Korea, New Zealand, Philippines, Russia, Spain, Switzerland and the United States. Thirty-eight papers were published in peer reviewed journals describing the antitumor and cytotoxic properties of 35 marine natural products belonging to four structural types, namely polyketides, terpenes, nitrogen-containing compounds and polysaccharides. The organisms yielding these bioactive marine compounds comprised a diverse group of marine animals, algae, fungi and bacteria. Antitumor pharmacological studies were reported for 17 marine natural products with an established mechanism of action. The Dolastins, tunicate derived-peptides with potent antitumor effect, advanced to Phase I anticancer clinical trials. *In vitro* cytotoxicity data was reported for 18 marine chemicals with undetermined mechanisms of action. This one-year overview thus provides evidence that 50 years after the discovery by Bergman and his co-workers of spongothymidine and spongouridine, there continues to be an active multinational research effort aimed at the discovery of novel antitumor agents from marine organisms.

Fifty years have passed since the seminal studies by Bergman (Bergmann and Feeney 1951; Bergmann and Burke 1955) that resulted in the discovery of spongothymidine and spongouridine from the sponge *Tethya crypta*. This finding led to the synthesis of arabinosyl cytosine (Ara-C), currently sold by the Pharmacia & Upjohn Company under the brand name Cytosar-U<sup>®</sup>, and which presently remains the only marine-derived anticancer agent in continuous clinical use, even though there has been continuous funding for this type of research over the past several decades. Currently, the CRISP database lists 17 projects directly funded by the National Institutes of Health in the area of marine antitumor chemistry and pharmacology.

The purpose of this article is to present an overview of research published during 1998 in the field of marine antitumor pharmacology. The articles included in this paper were retrieved from the National Library of Medicine via Medline<sup>®</sup>, Ovid Technologies, Inc.'s OVID database and MarinLit, a database dedicated to the

marine natural products literature. It is possible that some relevant articles were missed, but it is the hope of the author that this number is small. Only those articles reporting on the antitumor or cytotoxic activity of marine compounds with established chemical structures were included in this review and are presented in alphabetical order in *Table 1* or *Table 2*. Those papers reporting on preclinical and/or clinical antitumor research with marine chemicals with *determined* mechanisms of action have been included in *Table 1*. All other articles describing cytotoxicity to either murine or human tumors by marine natural products with *undetermined* mechanisms of action are grouped in *Table 2*. Due to space limitations, publications on the antitumor or cytotoxic activity of extracts or structurally uncharacterized marine compounds have not been included in this brief overview.

*Table 1* includes 20 reports on antitumor research involving 17 marine compounds with determined mechanisms of action that included *in vitro* and/or *in vivo* studies with human cancer cell lines. The marine chemicals Agosterol A, Jasplakinolide and Naamidine A were isolated from *Porifera* (sponges); Aplidine, Dolastin and Ecteinascidin from *Chordata* (tunicates); Eleutherobin and Sarcodictyin from *Cnidaria* (soft corals); Bryostatin from Ectoprocta (Bryozoa), 4 Phyla included in Kingdom *Animalia*. Curacin D, Dehydrothysiferol, Spirulan, Tolyporphin were derived from blue-green algae while Octalactin A was derived from bacteria (Kingdom *Monera*). Stypodiol was isolated from an alga from the Phylum *Phaeophyta* (Kingdom *Plantae*). Following the chemical classification proposed by Schmitz et al. (Schmitz et al., 1993), the marine natural products in *Table 1* fall into four chemical classes: polyketides (Bryostatins and Curacin D), terpenes (Agosterol A, Dehydrothysiferol, Eleutherobin, Sarcodictyins and Stypodiol), nitrogen-containing compounds (Aplidine, Auristastatin, Dolastin, Ecteinascidin, Jasplakinolide, Naamidine A and Tolyporphin) and polysaccharides (Spirulan). Considerable information is available for the 17 marine compounds included in *Table 1* at the mechanistic level. Distinct biochemical mechanisms have been indentified, including multidrug resistance reversal and protein kinase C binding, as well as inhibition of tubulin polimerization, protein synthesis, guanine binding, epidermal growth factor receptor, heparanase, acyl CoA:cholesterol-O-acyl transferase and the cell-cycle. Although antitumor studies involving human tumor cell lines with these 17 marine natural products were mostly of a preclinical nature (both *in vitro* and *in vivo*), a clinical anticancer trial with a synthetic Dolastin analog was reported during 1998 (Villalona-Calero et al., 1998).

The laboratories that reported the articles listed in Table 1 were located in the USA (14 papers), Spain (4 papers), Japan and France (2 papers each), while Germany, Austria, Switzerland, Italy, the Netherlands and Chile contributed one paper each.

In a similar manner, Table 2, lists 18 marine natural products with potential antitumor activity because they demonstrated activity in cytotoxicity assays. However, in contrast to the compounds listed in Table 1, no detailed mechanism of action studies have been completed so far with any of these compounds, with the exception of cytotoxicity tests against panels of human or murine tumor cell lines. The marine natural products Agelastin, Bolinaquinone, Crellastatin, Gymnastatin, Haliclonyclamine, Scalarane and Sesterstatin were isolated from Porifera (sponges); Lobatamide, Comoramide and Mayotamide from Chordata (tunicates); Capnellene and Sarcophine from Cnidaria (soft corals); Asteriidoside, Frondoside and a lectin from Echinodermata (seastar and cucumber, respectively); Cephalostatin from the Annelida (worm), 5 Phyla included in Kingdom Animalia. Cryptoxanthin was isolated from an alga from Phylum Phaeophyta (Kingdom Plantae) while Aspergillamide was derived from marine fungi (Kingdom Fungi). Once more, following the chemical classification proposed by Schmitz et al. (Schmitz et al., 1993), these 18 marine natural products can be assigned to three chemical classes: polyketides (Lobatamides), terpenes (Asteriidosides, Bolinaquinone, Capnellenes, Cephalostatin, Crellastatin, Cryptoxanthin, Frondoside, Sarcophine, Scalarane, Sesterstatin) and nitrogen-containing compounds (Agelastatins, Aspergillamides, Comoramides, Mayotamides, Gymnastatins, Haliclonyclamines, Lectin). The cytotoxic marine compounds listed in Table 2 were reported by investigators in the USA (7 papers), France (3 papers), Australia, Italy, Korea and Japan (2 papers each), while Israel, the Phillipines, Russia and the U.K. contributed one paper each.

In conclusion, this brief overview leads the author to concur with a recent review by D'Incalci (D'Incalci 1998) that there is "... some hope for marine natural products..." as human anticancer agents. Two specially significant examples are the Dolastins, that advanced to Phase I clinical trials in patients with advanced solid malignancies (colorectal, lung, melanoma, breast, kidney, jejunum) (Villalona-Calero et al., 1998) and the Ecteinascidins, shown to be active against human breast, non-small-cell lung, ovarian cancer and melanoma xenografts (Izbicka et al., 1998; Valoti et al., 1998). Furthermore, although a number of novel cytotoxic marine compounds have been reported during 1998,

additional studies are clearly required to complete their pharmacological characterization. Thus the 1998 anticancer research literature provides convincing evidence that 50 years after the discovery by Bergman and his co-workers of spongothymidine and spongouridine, there continues to be a sustained multinational effort aimed at the discovery of novel antitumor agents derived from marine organisms.

### References

- Amagata T, Doi M, Ohta T, Minoura K and Numata A (1998) Absolute stereostructures of novel cytotoxic metabolites, Gymnastatins A-E, from a *Gymnascella* species separated from a *Halichondria* sponge. *J Chem Soc Perkin Trans 1* **21**:3585-3599.
- Anderson GT, Chase CE, Koh Y, Stien D, Weinreb, SM and Shang M (1998) Studies on total synthesis of the cytotoxic marine alkaloid Agelestatin A. *J Org Chem* **63**:7594-7595.
- Aoki S, Yoshioka Y, Miyamoto Y, Higuchi K, Setiawan A, Murakami N, Chen Z, Sumizawa T, Akiyama S and Kobayashi, M (1998) Agosterol A, a novel polyhydroxylated sterol acetate reversing multidrug resistance from a marine sponge of *Spongia* sp. *Tetrahedron Lett* **39**:6303-6306.
- Avilov SA, Drozdova OA, Kalinin VI, Kalinovskiy AI, Stonik VA, Gudimova EN, Riguera R and Jimenez C (1998) Frondoside C, a new nonholostane triterpene glycoside from the sea cucumber *Cucumaria frondosa*: structure and cytotoxicity of its desulfated derivative. *Can J Chem* **76**:137-141.
- Bergmann W and Feeney RJ (1951) Contributions to the study of marine products. XXXII. The nucleosides of sponges. *J Org Chem* **16**:981-987.
- Bergmann W and Burke DC (1955) Contributions to the study of marine products. XXXIX. The nucleosides of sponges. III. Spongothymidine and spongouridine. *J Org Chem* **20**: 1501-1507.
- Clark RJ, Field, KL, Charan RD, Garson MJ, Brereton IM and Willis AC (1998) The haliclonyclamines, cytotoxic tertiary alkaloids from the tropical marine sponge *Haliclona* sp. *Tetrahedron* **54**:8811-8826.
- Copp BR, Fairchild CR, Cornell L, Casazza AM, Robinson S and Ireland CM (1998) Naamidine A is an antagonist of the epidermal growth factor receptor and an *in vivo* active antitumor agent. *J Med Chem* **41**:3909-3911.
- D'Auria MV, Giannini C, Zampella A, Minale L, Debitus C and Roussakis C (1998) Crellastatin A: a cytotoxic bis-steroid sulfate from the Vanuatu marine sponge *Crella* sp. *J Org Chem* **63**:7382-7388.

*References continued on page 163...*

# MARINE PHARMACOLOGY

**Table 1: 1998 Antitumor pharmacology of marine natural products with determined mechanisms of action.**

<b>Compound Reference</b>	<b>Organism<sup>1</sup></b>	<b>Chemistry</b>	<b>MMOA<sup>2</sup></b>	<b>Country<sup>3</sup></b>
Agosterol A (Aoki <i>et al.</i> , 1998)	sponge	terpene	MDR reversal	JAPN
Aplidine (Depenbrock <i>et al.</i> , 1998)	tunicate	depsipeptide	prot. synth. inhibit.	GER, SPA, USA
Auristatin (Mohammad <i>et al.</i> , 1998)	synthet.	peptide	tubulin pol. inhibit.	USA
Bryostatins (Wender <i>et al.</i> , 1998)	bryozoa	macrolide	PKC binding	USA
Curacin D (Marquez <i>et al.</i> , 1998)	alga	polyketide	tubulin pol. inhibit.	USA
Dehydrothysiferol (Pec <i>et al.</i> , 1998)	alga	terpene	S-phase inhibit.	ATRIA, USA
Dolastin 10 (Poncet <i>et al.</i> , 1998)	synthet.	peptide	tubulin pol. inhibit.	FRA
Dolastin 10 (Turner <i>et al.</i> , 1998)	tunicate	peptide	tubulin pol. inhibit.	USA
Dolastin analog (Villalona-Calero <i>et al.</i> , 1998)	synthet.	peptide	tubulin pol. inhibit.	USA
Ecteinasclidin (Ghielmini <i>et al.</i> , 1998)	tunicate	quinoline	Guanine binding	SWI, SPA
Ecteinasclidin (Izbicka <i>et al.</i> , 1998)	tunicate	quinoline	Guanine binding	SPA, USA
Ecteinasclidin (Valoti <i>et al.</i> , 1998)	tunicate	quinoline	Guanine binding	ITA, SPA, NETH
Eleutherobin (Long <i>et al.</i> , 1998)	coral	terpene	tubul. pol. prom.	USA
Jasplakinolide (Takeuchi <i>et al.</i> , 1998)	sponge	peptide	tubul. pol. prom.	USA
Naamidine A (Copp <i>et al.</i> , 1998)	sponge	imidazole	EGF inhibition	USA
Octalactin A (Perchellet <i>et al.</i> , 1998)	bacteria	polyketide	tubulin pol. inhibit.	USA
Sarcodictyins (Nicolaou <i>et al.</i> , 1998)	coral	terpene	tubul. pol. prom.	USA
Spirulan (Mishima <i>et al.</i> , 1998)	alga	polysaccharide	heparanase inhibit.	JPAN
Stypodiol (Depix <i>et al.</i> , 1998)	alga	terpenoid	tubul. pol. prom.	Chile
Tolyporphin (Morliere <i>et al.</i> , 1998)	alga	pyrrol	ACAT inhibit.	FRA, USA, NZ

(1) synthet.:synthetic

(2) MMOA: molecular mechanism of action ; ACAT inh: acyl CoA:cholesterol-O-acyl transferase inhibition; EGF: epidermal growth factor; inhibit.: inhibition ; MDR, multidrug resistance; pol.: polymerization; PKC: protein kinase C; prot. synth.: protein synthesis; tub. pol. prom.: tubulin polymerization promotion

(3) ATRIA: Austria, FRA: France, GER: Germany, ITA: Italy, JAPN: Japan, NETH: Netherlands, NZ: New Zealand, SPA:Spain, SWI: Switzerland.

## MARINE PHARMACOLOGY

**Table 2: 1998 Antitumor pharmacology of marine natural products with undetermined mechanism of action**

<b>Compound Reference</b>	<b>Organism</b>	<b>Chemistry</b>	<b>Cell line<sup>2</sup></b>	<b>Country<sup>3</sup></b>
Agelastatins (Anderson <i>et al.</i> , 1998)	sponge	alkaloid	N.R.	USA
Aspergillamides (Toske <i>et al.</i> , 1998)	fungus	peptide	HU	USA
Asteriidosides (De Marino <i>et al.</i> , 1998)	starfish	sterol	HU	ITAL, FRA
Bolinaquinone (de Guzman <i>et al.</i> , 1998)	sponge	terpene	HU	USA, PHIL
Capnellenes (Morris <i>et al.</i> , 1998)	coral	terpene	HU	UK
Cephalostatins (Pettit <i>et al.</i> , 1998)	worm	sterol	HU, MU	USA
Comora & Mayotamides (Rudi <i>et al.</i> , 1998)	tunicate	peptides	HU	ISR, FRA
Crellastatin (D'Auria <i>et al.</i> , 1998)	sponge	sterol	HU	ITAL, FRA
Cryptoxanthin (Park <i>et al.</i> , 1998)	alga	terpene	N.R.	KOR
Fronoside (Avilov <i>et al.</i> , 1998)	cucumber	terpene	HU, MU	RUS, SPA
Gymnastatins (Amagata <i>et al.</i> , 1998)	fungus	(1)	MU	JAPN
Haliclonacyclamines (Clark <i>et al.</i> , 1998)	sponge	alkaloid	MU	AUS
Lectin (Shon <i>et al.</i> , 1998)	seastar	protein	MU, HU	KOR
Lobatamides (McKee <i>et al.</i> , 1998)	tunicate	macrolide	HU	AUS, USA
Sarcophine (El Sayed <i>et al.</i> , 1998)	coral	terpene	MU	USA
Scalarane (Tsuchiya <i>et al.</i> , 1998)	sponge	terpene	MU, HU	JAPN
Sesterstatins (Pettit <i>et al.</i> , 1998)	sponge	terpene	MU	USA

(1) Nitrogen-containing compound, tyrosine-based metabolite

(2) N.R.: not reported, HU:human, MU:murine

(3) AUS: Australia, FRA: France, ITAL: Italy, KOR: Korea, ISR: Israel, JAPN: Japan, PHIL: Philippines, RUS: Russia, SPA: Spain, UK: United Kingdom.

## MARINE PHARMACOLOGY

References continued from page 160...

D'Incalci M (1998) Some hope from marine natural products [editorial]. *Ann Oncol* **9**:937-938.

De Guzman FS, Copp BR, Mayne CL, Concepcion GP, Mangalindan GC, Barrows LR and Ireland CM (1998) Bolinaquinone: a novel cytotoxic sesquiterpene hydroxyquinone from a Phillipine *Dysidea* sponge. *J Org Chem* **63**:8042-8044.

De Marino S, Iorizzi M, Palagiano E, Zollo F and Roussakis C (1998) Starfish saponins. 55. Isolation, structure elucidation, and biological activity of the steroid oligoglycosides from an Antarctic starfish of the family *Asteriidae*. *J Nat Prod (Lloydia)* **61**:1319-1327.

Deppenbrock H, Peter R, Faircloth GT, Manzanares I, Jimeno J and Hanauske AR (1998) In vitro activity of Aplidine, a new marine-derived anti-cancer compound, on freshly explanted clonogenic human tumour cells and haematopoietic precursor cells. *Br J Cancer* **78**:739-744.

Dexis MS, Martinez J, Santibanez F, Roviroso J, San Martin A and Maccioni RB (1998) The compound 14-keto-Stypodioldiacetate from the algae *Stypopodium flabelliforme* inhibits microtubules and cell proliferation in DU-145 human prostatic cells. *Mol Cell Biochem* **187**:191-199.

El Sayed KA, Hamann MT, Waddling CA, Jensen C, Lee SK, Dunstan CA and Pezzuto, JM (1998) Structurally novel bioconversion products of the marine natural product Sarcophine effectively inhibit JB6 cell transformation. *J Org Chem* **63**:7449-7455.

Ghielmini M, Colli E, Erba E, Bergamaschi D, Pampallona S, Jimeno J, Faircloth G and Sessa C (1998) In vitro schedule-dependency of myelotoxicity and cytotoxicity of Ecteinascidin 743 (ET-743). *Ann Oncol* **9**:989-993.

Izbicka E, Lawrence R, Raymond E, Eckhardt G, Faircloth G, Jimeno J, Clarck G, and Von Hoff DD (1998) In vitro antitumor activity of the novel marine agent, Ecteinascidin- 743 (ET-743, NSC-648766) against human tumors explanted from patients. *Ann Oncol* **9**:981-987.

Long BH, Carboni JM, Wasserman AJ, Cornell LA, Casazza AM, Jensen PR, Lindel T, Fenical W and Fairchild CR (1998) Eleutherobin, a novel cytotoxic agent that induces tubulin polymerization, is similar to Paclitaxel (Taxol). *Cancer Res* **58**:1111-1115.

Marquez B, Verdier-Pinard P, Hamel E and Gerwick WH (1998) Curacin D, an antimetabolic agent from the marine cyanobacterium *Lyngbya majuscula*. *Phytochemistry* **49**:2387-2389.

McKee TC, Galinis DL, Pannell LK, Cardellina JH, Laakso J, Ireland CM, Murray L, Capon RJ and Boyd MR (1998) The

Lobatamides, novel cytotoxic macrolides from southwestern Pacific tunicates. *J Org Chem* **63**:7805-7810.

Mishima T, Murata J, Toyoshima M, Fujii H, Nakajima M, Hayashi T, Kato T and Saiki I (1998) Inhibition of tumor invasion and metastasis by calcium spirulan (Ca-SP), a novel sulfated polysaccharide derived from a blue-green alga, *Spirulina platensis*. *Clin Exp Metastasis* **16**:541-550.

Mohammad RM, Varterasian ML, Almatchy VP, Hannoudi GN, Pettit GR and Al-Katib A (1998) Successful treatment of human chronic lymphocytic leukemia xenografts with combination biological agents Auristatin PE and Bryostatins 1. *Clin Cancer Res* **4**:1337-1343.

Morliere P, Maziere JC, Santus R, Smith CD, Prinsep MR, Stobbe CC, Fenning MC, Goldberg JL and Chapman JD (1998) Tolyporphin: a natural product from cyanobacteria with potent photosensitizing activity against tumor cells *in vitro* and *in vivo*. *Cancer Res* **58**:3571-3578.

Morris LA, Jaspars M, Adamson K, Woods S and Wallace HM (1998) The Capnellenes revisited: new structures and new biological activity. *Tetrahedron* **54**:12953-12958.

Nicolaou KC, Kim S, Pfefferkorn J, Xu J, Ohshima T, Hosokawa S, Vourloumis D and Li T (1998) Synthesis and biological activity of Sarcodictyins. *Angew Chem Int Ed Engl* **37**:1418-1421.

Park Y, Kim I, Yoo S, Ahn J, Lee T, Park D and Kim S (1998) Elucidation of anti-tumor initiator and promoter derived from seaweed-3: anti-tumor promoters of *Ecklonia stolonifera* extracts. *Han'guk Susan Hakhoiji* **31**:587-593.

Pec MK, Hellan M, Moser-Thier K, Fernandez JJ, Souto ML and Kubista E (1998) Inhibitory effects of a novel marine terpenoid on sensitive and multidrug resistant KB cell lines. *Anticancer Res* **18**:3027-3032.

Perchellet JR, Perchellet EM, Newell SW, Freeman JA, Ladesich JB, Jeong YM, Sato N and Buszek K (1998) Antitumor activity of novel Octalactin A analogs in murine leukemic cells *in vitro*. *Anticancer Res* **18**:97-106.

Pettit GR, Cichacz A, Tan R, Hoard MS, Melody N and Pettit RK (1998) Antineoplastic agents. 386. Isolation of Sesterstatins 1-3 from the marine sponge *Hyrtios erecta*. *J Nat Prod* **61**:13-16.

Pettit GR, Tan R, Xu J, Ichihara Y, Williams MD and Boyd MR (1998) Antineoplastic agents. 398. Isolation and structure elucidation of Cephalostatins 18 and 19. *J Nat Prod* **61**:955-958.

Poncet J, Hortala L, Busquet M, Gueritte-Voegelein F, Thoret S, Pierre A, Atassi G and Jouin P (1998) Synthesis and antiproliferative activity of a cyclic analog of Dolastatin 10. *Bioorg Med Chem Lett* **8**:2855-2858.

## MARINE PHARMACOLOGY

Rudi A, Akin M, Gaydou EM and Kashman Y (1998) Four new cytotoxic cyclic hexa- and heptapeptides from the marine ascidian, *Didemnum molle*. *Tetrahedron* **54**:13203-13210.

Schmitz FJ, Bowden BF and Toth SI (1998) Antitumor and cytotoxic compounds from marine organisms, in *Marine Biotechnology* (Attaway DH and Zaborsky OR eds) pp197-308, Plenum Press, New York.

Shon YH, Jeune KH, Choi SJ and Chung SR (1998) Antitumor effect of *Asterina pectinifera* lectin on ascitic tumor. *Yakhak Hoeji* **42**:368-394.

Takeuchi H, Ara G, Sausville EA and Teicher B (1998) Jaspilakinolide: interaction with radiation and hyperthermia in human prostate carcinoma and Lewis lung carcinoma. *Cancer Chemother Pharmacol* **42**:491-496.

Toske SG, Jensen PR, Kauffman CA and Fenical W (1998) Aspergillamides A and B: modified cytotoxic tripeptides produced by a marine fungus of the genus *Aspergillus*. *Tetrahedron* **54**:13459-13466.

Tsuchiya N, Sato A, Hata T, Sato N, Sasagawa K and Kobayashi T (1998) Cytotoxic scalarane sesterterpenes from a sponge, *Hyrtilis erecta*. *J Nat Prod* **61**:468-473.

Turner T, Jackson WH, Pettit GR, Wells A and Kraft AS (1998) Treatment of human prostate cancer cells with Dolastatin 10, a peptide isolated from a marine shell-less mollusc. *Prostate* **34**: 75-181.

Valoti G, Nicoletti MI, Pellegrino A, Jimeno J, Hendricks H, D'Incalci M, Faircloth G and Giavazzi R (1998) Ecteinascidin-743, a new marine natural product with potent antitumor activity on human ovarian carcinoma xenografts. *Clin Cancer Res* **4**:1977-1983.

Villalona-Calero MA, Baker SD, Hammond L, Aylesworth C, Eckhardt SG, Kraynak M, Fram R, Fischkoff S, Velagapudi R, Toppmeyer D, Razvillas B, Jakimowicz K, Von Hoff DD and Rowinsky E (1998) Phase I and pharmacokinetic study of the water-soluble Dolastatin 15 analog LU103793 in patients with advanced solid malignancies. *J Clin Oncol* **16**:2770-2779.

Wender PA, DeBrabander J, Harran PG, Jimenez JM, Koehler MFT, Lippa B, Park CM, Siedenbiedel C and Pettit GR (1998) The design, computer modeling, solution structure, and biological evaluation of synthetic analogs of Byostatin 1. *Proc Natl Acad Sci USA* **95**:6624-6629.

### Acknowledgments

The author wishes to thank Virginia Lehmann, School of Chemical Sciences, University of Illinois at Urbana-Champaign, for helping locate many of the articles referenced in this review as well as with the chemical classification of the marine chemicals. Virginia Lehmann's graduate Sea Grant traineeship as well as this

manuscript was funded by a grant to the author from the National Sea Grant College Program, National Oceanic and Atmospheric Administration, U.S. Department of Commerce, under grant number NA66RG0477, project R/MP 73 through the California Sea Grant College System. The views expressed herein are those of the author and do not necessarily reflect the views of NOAA or any of its sub-agencies. The U.S. Government is authorized to reproduce and distribute for governmental purposes.

(1)  
Department of Pharmacology  
Chicago College of Osteopathic Medicine  
Midwestern University  
555 31st Street  
Downers Grove, Illinois 60515  
USA

Phone: (630) 515-6951

Fax: (630) 971-6414

E-mail: amayer@midwestern.edu

